XKEMQ.PK.

[GatewayStocks]

Alembic gives XKEM 75 countries throughout the world in our distribution network. What a nice head start. Access to R&D facilities. I think we have a winner here...GLTA

[GatewayStocks]

Xechem Files Orphan Drug Application with the FDA For The Anti-Sickling Compound Licensed From Virginia Commonwealth University
Tuesday March 14, 6:30 am ET


NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--March 14, 2006--Xechem International, Inc. (OTC BB: XKEM - News) Xechem International announced today that it has submitted its Orphan Drug Application for the five-membered heterocyclic anti-sickling compound known as 5-HMF to the United States Food and Drug Administration (FDA).
ADVERTISEMENT


Research Shows Efficacy of 5-HMF

As reported on December 9, 2005, this promising compound has shown excellent biological activity in preliminary testing as an anti-sickling agent. This was discovered by Prof. Donald Abraham and his team of scientists from Virginia Commonwealth University (VCU), Richmond, VA in collaboration with a team of doctors and scientists at NHLBI Sickle Cell Disease Reference Laboratory at The Children's Hospital of Philadelphia (CHOP), University of Pennsylvania led by Professor Toshio Asakura. Xechem has acquired the exclusive, worldwide rights from VCU for the production, sales and marketing of 5-HMF for use in the battle against SCD.

Research has shown that the 5-HMF compound is not only a natural product with very little if any toxicity, it also appears to be an effective anti-sickling agent which has shown high affinity for hemoglobin and is very active in genetically modified transgenic (Tg) mice. Professor Abraham of VCU has characterized this compound as "the best potential antisickling agent in 30 years research to be discovered by (VCU's) research group." See Xechem's December 9, 2005 Press Release.

If granted, Orphan Drug status will afford Xechem seven years of marketing exclusivity for the drug once the drug is ultimately approved by the FDA, and will offer Xechem tax credits, filing fee waivers and certain other statutory benefits.

5-HMF Complements Xechem's Existing Arsenal for Treatment of Sickle Cell Disease

According to Xechem's Chairman and CEO, Dr. Ramesh C. Pandey, "This new compound licensed from VCU represents the latest effort undertaken by Xechem in the fight against Sickle Cell Disease (SCD), and adds to Xechem's existing arsenal of NICOSAN(TM)/HEMOXIN(TM), an all natural, phyto-pharmaceutical product that has shown enormous promise for SCD sufferers. NICOSAN(TM)/HEMOXIN(TM) has already been designated as an Orphan Drug both in the United States and in European Union countries. It was acquired under an exclusive worldwide license from the National Institute for Pharmaceutical Research and Development (NIPRD), Ministry of Health, Government of Nigeria, Between the progress we have been making in bringing NICOSAN(TM) to market, and this exciting new heterocyclic pharmaceutical agent being developed in collaboration with VCU, we expect Xechem to be front and center in eventually offering the most viable and efficacious treatments to patients suffering with SCD around the world." Dr. Pandey added that the Company intends shortly to prepare and file an Investigational New Drug (IND) Application for submission to the FDA for both HEMOXIN(TM) and 5-HMF.

About Sickle Cell Disease

Sickle Cell Disease is a genetic blood disorder caused by an abnormality in the hemoglobin molecule. Patients with this disease often produce stiff, abnormally shaped cells that do not flow freely through blood vessels, creating clogs in the vessels, which in turn cut off the flow of normal hemoglobin and oxygen to the body. In Nigeria alone, more than 25% of the population are carriers of the SCD trait and over 4.5 million Nigerians (about 5% of the population) are actually afflicted with the disease. Approximately 15 million people, mostly in sub-Saharan Africa, are believed to suffer from this disease worldwide.

About Xechem

Xechem International, Inc. is a development stage biopharmaceutical company focusing on anticancer, antiviral (including AIDS), antifungal, Sickle Cell Disease (SCD), antimalarial and antibacterial products from natural sources, including microbial and marine organisms as well as the development of phyto-pharmaceuticals and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its primary attention and resources are currently being directed toward the development and commercial launch of the phyto-pharmaceutical NICOSAN(TM)/HEMOXIN(TM), which has shown efficacy in the treatment of SCD.

[GatewayStocks]

Nigerian Govt. President Olusegun Obasanjo said they will by June launch NIPRISAN (HEMOXIN(TM)), the locally produced drug for sickle cell disorder.

This drug "IS" going to be Launched!

[tacoma]

This is a great stock -

News Release://
Xechem Files Orphan Drug Application with the FDA For The Anti-Sickling Compound Licensed From Virginia Commonwealth University
Tuesday March 14, 6:30 am ET


NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--March 14, 2006--Xechem International, Inc. (OTC BB: XKEM - News) Xechem International announced today that it has submitted its Orphan Drug Application for the five-membered heterocyclic anti-sickling compound known as 5-HMF to the United States Food and Drug Administration (FDA).
Research Shows Efficacy of 5-HMF

As reported on December 9, 2005, this promising compound has shown excellent biological activity in preliminary testing as an anti-sickling agent. This was discovered by Prof. Donald Abraham and his team of scientists from Virginia Commonwealth University (VCU), Richmond, VA in collaboration with a team of doctors and scientists at NHLBI Sickle Cell Disease Reference Laboratory at The Children's Hospital of Philadelphia (CHOP), University of Pennsylvania led by Professor Toshio Asakura. Xechem has acquired the exclusive, worldwide rights from VCU for the production, sales and marketing of 5-HMF for use in the battle against SCD.

Research has shown that the 5-HMF compound is not only a natural product with very little if any toxicity, it also appears to be an effective anti-sickling agent which has shown high affinity for hemoglobin and is very active in genetically modified transgenic (Tg) mice. Professor Abraham of VCU has characterized this compound as "the best potential antisickling agent in 30 years research to be discovered by (VCU's) research group." See Xechem's December 9, 2005 Press Release.

If granted, Orphan Drug status will afford Xechem seven years of marketing exclusivity for the drug once the drug is ultimately approved by the FDA, and will offer Xechem tax credits, filing fee waivers and certain other statutory benefits.

5-HMF Complements Xechem's Existing Arsenal for Treatment of Sickle Cell Disease

According to Xechem's Chairman and CEO, Dr. Ramesh C. Pandey, "This new compound licensed from VCU represents the latest effort undertaken by Xechem in the fight against Sickle Cell Disease (SCD), and adds to Xechem's existing arsenal of NICOSAN(TM)/HEMOXIN(TM), an all natural, phyto-pharmaceutical product that has shown enormous promise for SCD sufferers. NICOSAN(TM)/HEMOXIN(TM) has already been designated as an Orphan Drug both in the United States and in European Union countries. It was acquired under an exclusive worldwide license from the National Institute for Pharmaceutical Research and Development (NIPRD), Ministry of Health, Government of Nigeria, Between the progress we have been making in bringing NICOSAN(TM) to market, and this exciting new heterocyclic pharmaceutical agent being developed in collaboration with VCU, we expect Xechem to be front and center in eventually offering the most viable and efficacious treatments to patients suffering with SCD around the world." Dr. Pandey added that the Company intends shortly to prepare and file an Investigational New Drug (IND) Application for submission to the FDA for both HEMOXIN(TM) and 5-HMF.

About Sickle Cell Disease

Sickle Cell Disease is a genetic blood disorder caused by an abnormality in the hemoglobin molecule. Patients with this disease often produce stiff, abnormally shaped cells that do not flow freely through blood vessels, creating clogs in the vessels, which in turn cut off the flow of normal hemoglobin and oxygen to the body. In Nigeria alone, more than 25% of the population are carriers of the SCD trait and over 4.5 million Nigerians (about 5% of the population) are actually afflicted with the disease. Approximately 15 million people, mostly in sub-Saharan Africa, are believed to suffer from this disease worldwide.

About Xechem

Xechem International, Inc. is a development stage biopharmaceutical company focusing on anticancer, antiviral (including AIDS), antifungal, Sickle Cell Disease (SCD), antimalarial and antibacterial products from natural sources, including microbial and marine organisms as well as the development of phyto-pharmaceuticals and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its primary attention and resources are currently being directed toward the development and commercial launch of the phyto-pharmaceutical NICOSAN(TM)/HEMOXIN(TM), which has shown efficacy in the treatment of SCD.

[GatewayStocks]

took profits after the gap...looking for a new entry... news wasn't all I expected but will look for new entry...Great things are coming soon...GLTA

[listener]

Hi Gateway et al. I've been wondering if SouthEnd Stock Pickers & other promoters are still unwinding their position in XKEM since the big run up, with the assumption that no significant news is in the offing near term ?  XKEM has dropped -50% since the Mar 6th high despite additional good news.

The fact that the company's market cap of $7.2M is a trifle compared to potential long term market revs of +$500M in Nigeria according to company estimates for the lead Nicosan Sickle Cell Disease drug. Perhaps the word that production won't likely start until June (but possibly sooner) has pulled a lot of traders off to the sideline ?

Dr. Pandey, the CEO will be giving a speech at an Anti-Malarial drug conference in Africa on 3/21 but that doesn't in itself suggest any specific news would be generated out of that.

The company has several MD's & Ph'D's on staff; all with laudable career status. 450M shares outstanding, recent lawsuit win over Bristol Myers Squibb giving them $4.2M cash which allowed them to reacquire remaining interest in Nicosan from Alembic while retaining distribution rights worldwide. Paclitaxel now on the second burner and it could get white hot soon too.
Recent deal w/VCU on new heterocyclic getting Orphan Status for SCD makes XKEM the de facto leader in SCD worldwide. Production facility built, tons of raw product ready for processing into new Nicosan drug.

All the above and an extremely low market cap on a heavily shorted stock (still on the SHO's list) with great potential and endorsed by the President of Nigeria looks like a set up for a scorching stock by early summer if not early spring !

I'm not one to buy & hold penny stocks, but this one looks as tempting as any I've seen in a long while.

Your thoughts are welcomed....

[GatewayStocks]

I am just waiting for an new entry...I think it could go lower with not much news expected near term...Xkem at malaria conf. in Africa next week 21st...

[rv]

so, it seems, this drub has been a long time coming, but if approved by the FDA, it could really move.  but, one thing i dont' quite get, it's a 7 million dollar company, how do they pay for research?  or do they wait for a college professor, who makes 60k/year to find something and then go in a shower him w/ "royalties to come"?  

i'll keep this one on the radar....

[sir_joke]

xkem is really a holding company which outsources the research. It's budget therefore is small relative to biotechs in general... It funds itself mostly by private investors and debt to equity offerings. 

They will receive a huge profit from Hemoxin/nicosan. the restrucutring of it's financial obligations to Alembic are extremely beneficial to Xechem.

cheers,
SJ

$10 pps in 2 years from this point.

[listener]

Sir Joke: I agree. Unfortunately there are still more daytraders in/out of stock on daily basis than long term investors.

This stock should show a sustained upward move like XSNX but for some reason it's not.

Imagine for a moment: It would take only 450 long term investors to buy the entire float for under $8M !  If I could, I'd buy it all myself.

Obviously the SHO list of naked shorts means there is a artificially larger float, but based on what ?
What unforeseen negative news gives these shorts the balls to short it when the President of Nigeria already endorses the drug and their main source of financing took out warrants at over 10X current share price ?

[brucey]

time to grab XKEM again.
http://www.americanbulls.com/StockPage.asp?CompanyTicker=XKEM&MarketTicker=OTC&TYP=S

[waxweazle]

Today XKEM is gone from the short list!!

uptrend is broken!

nice mmove on Volume today..
to be continue

[sir_joke]

Moving well today.

bottom at $.0013.

Off the SHO list and on to profits.

Traders are having a field day.

cheers,
SJ

[waxweazle]

nice setup like in Februar!!

MACD today Trigger!!!

im in

[waxweazle]

MM play this
The <bollinger come togther so  this stock can goo!!!!